» Articles » PMID: 28781374

IL-11 Induces Differentiation of Myeloid-derived Suppressor Cells Through Activation of STAT3 Signalling Pathway

Overview
Journal Sci Rep
Specialty Science
Date 2017 Aug 8
PMID 28781374
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Myeloid-derived suppressor cells (MDSCs) are immune negative regulators in the tumour microenvironment. Interleukin (IL)-11, a member of IL-6 family cytokines, functions through the unique receptor IL-11 receptor α coupled with the common signal transducer gp130. IL-11-gp130 signalling causes activation of the JAK/STAT3 pathway. IL-11 is highly upregulated in many types of cancers and one of the most important cytokines during tumourigenesis and metastasis. However, the precise effect of IL-11 on differentiation into MDSCs is still unknown. Here, we found that CD11bCD14 monocytic MDSCs were generated from peripheral blood mononuclear cells (PBMCs) of healthy donors in the presence of IL-11. IL-11-conditioned PBMCs induced higher expression of immunosuppressive molecules such as arginase-1. A reduction of T-cell proliferation was observed when MDSCs generated in the presence of IL-11 were co-cultured with CD3/CD28-stimulated, autologous T cells of healthy donors. Culture of normal PBMCs with IL-11 led to STAT3 phosphorylation and differentiation into MDSCs via STAT3 activation. We confirmed expressions of both IL-11 and phosphorylated STAT3 in tumour tissues of colorectal cancer patients. These findings suggest that monocytic MDSCs may be induced by IL-11 in the tumour microenvironment. Thus, IL-11-mediated regulation in functional differentiation of MDSCs may serve as a possible target for cancer immunotherapy.

Citing Articles

Integrated Transcriptome Profiling and Pan-Cancer Analyses Reveal Oncogenic Networks and Tumor-Immune Modulatory Roles for FABP7 in Brain Cancers.

Lee Y, Flores C, Lefton M, Bhoumik S, Owada Y, Gerstner J Int J Mol Sci. 2024; 25(22).

PMID: 39596296 PMC: 11594725. DOI: 10.3390/ijms252212231.


Potential marker subset of blood-circulating cytokines on hematopoietic progenitor-to-Th1 pathway in COVID-19.

Takashima Y, Inaba T, Matsuyama T, Yoshii K, Tanaka M, Matsumoto K Front Med (Lausanne). 2024; 11:1319980.

PMID: 38476443 PMC: 10927758. DOI: 10.3389/fmed.2024.1319980.


Pharmacologic inhibition of IL11/STAT3 signaling increases MHC-I expression and T cell infiltration.

Xiong W, Chen Y, Zhang C, Li J, Huang H, Zhu Y J Transl Med. 2023; 21(1):416.

PMID: 37365574 PMC: 10294373. DOI: 10.1186/s12967-023-04079-6.


Oncolytic BHV-1 Is Sufficient to Induce Immunogenic Cell Death and Synergizes with Low-Dose Chemotherapy to Dampen Immunosuppressive T Regulatory Cells.

Davola M, Cormier O, Vito A, El-Sayes N, Collins S, Salem O Cancers (Basel). 2023; 15(4).

PMID: 36831636 PMC: 9953776. DOI: 10.3390/cancers15041295.


Central Roles of STAT3-Mediated Signals in Onset and Development of Cancers: Tumorigenesis and Immunosurveillance.

Hashimoto S, Hashimoto A, Muromoto R, Kitai Y, Oritani K, Matsuda T Cells. 2022; 11(16).

PMID: 36010693 PMC: 9406645. DOI: 10.3390/cells11162618.


References
1.
Bellone G, Smirne C, Mauri F, Tonel E, Carbone A, Buffolino A . Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother. 2005; 55(6):684-98. PMC: 11031060. DOI: 10.1007/s00262-005-0047-0. View

2.
Diaz-Montero C, Salem M, Nishimura M, Garrett-Mayer E, Cole D, Montero A . Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2008; 58(1):49-59. PMC: 3401888. DOI: 10.1007/s00262-008-0523-4. View

3.
Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L . Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007; 13(7):828-35. PMC: 2135607. DOI: 10.1038/nm1609. View

4.
Zhang Y, Wakita D, Chamoto K, Narita Y, Matsubara N, Kitamura H . Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs. Int Immunol. 2006; 19(2):151-61. DOI: 10.1093/intimm/dxl132. View

5.
Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kubler H . Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2008; 14(24):8270-8. DOI: 10.1158/1078-0432.CCR-08-0165. View